194 related articles for article (PubMed ID: 19250630)
1. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5.
Maeda H; Yonou H; Yano K; Ishii G; Saito S; Ochiai A
Biochem Biophys Res Commun; 2009 Apr; 381(3):311-6. PubMed ID: 19250630
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.
Nakamura M; Miyamoto S; Maeda H; Ishii G; Hasebe T; Chiba T; Asaka M; Ochiai A
Biochem Biophys Res Commun; 2005 Aug; 333(3):1011-6. PubMed ID: 15964556
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth and regulation of IGFs and VEGF in human prostate cancer cell lines by shikonin analogue 93/637 (SA).
Gaddipati JP; Mani H; Shefali ; Raj K; Mathad VT; Bhaduri AP; Maheshwari RK
Anticancer Res; 2000; 20(4):2547-52. PubMed ID: 10953325
[TBL] [Abstract][Full Text] [Related]
6. The IGF axis in the prostate.
Cohen P; Peehl DM; Rosenfeld RG
Horm Metab Res; 1994 Feb; 26(2):81-4. PubMed ID: 8200618
[TBL] [Abstract][Full Text] [Related]
7. Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis.
Beattie J; Phillips K; Shand JH; Szymanowska M; Flint DJ; Allan GJ
J Mol Endocrinol; 2005 Feb; 34(1):163-75. PubMed ID: 15691886
[TBL] [Abstract][Full Text] [Related]
8. Zinc partitions insulin-like growth factors (IGFs) from soluble IGF binding protein (IGFBP)-5 to the cell surface receptors of BC3H-1 muscle cells.
McCusker RH; Novakofski J
J Cell Physiol; 2003 Dec; 197(3):388-99. PubMed ID: 14566968
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of a serine protease that preferentially cleaves insulin-like growth factor binding protein-5.
Hou J; Clemmons DR; Smeekens S
J Cell Biochem; 2005 Feb; 94(3):470-84. PubMed ID: 15534875
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I.
Kawada M; Inoue H; Arakawa M; Ikeda D
Anticancer Res; 2008; 28(2A):721-30. PubMed ID: 18507013
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
12. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
13. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
14. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.
Cohen P; Peehl DM; Graves HC; Rosenfeld RG
J Endocrinol; 1994 Sep; 142(3):407-15. PubMed ID: 7525824
[TBL] [Abstract][Full Text] [Related]
15. Effect of 17beta-estradiol on apoptosis, IGF system components and gelatinases A and B in prostate cancer cells (PC-3).
Kanagaraj P; Vijayababu MR; Ilangovan R; Senthilkumar K; Venkataraman P; Aruldhas MM; Arunakaran J
Clin Chim Acta; 2007 Feb; 377(1-2):70-8. PubMed ID: 17083925
[TBL] [Abstract][Full Text] [Related]
16. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells.
Tenta R; Sourla A; Lembessis P; Luu-The V; Koutsilieris M
Horm Metab Res; 2005 Oct; 37(10):593-601. PubMed ID: 16278781
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Zhigang Z; Jieming L; Su L; Wenlu S
J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
[TBL] [Abstract][Full Text] [Related]
18. The divergent effect of insulin-like growth factor binding protein (IGFBP) - 1 on IGF-induced Steroidogenesis in bovine adrenocortical cells is not due to its phosphorylation status.
Fottner C; Spöttl G; Weber MM
Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):232-9. PubMed ID: 17479439
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of osteoblastic bone metastasis of prostate cancer].
Yonou H; Ogawa Y; Ochiai A
Clin Calcium; 2006 Apr; 16(4):557- 64. PubMed ID: 16582505
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence?
Meinbach DS; Lokeshwar BL
Urol Oncol; 2006; 24(4):294-306. PubMed ID: 16818181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
